Taysha Gene Therapies, Inc.
TSHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -46.1% | 517.5% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 0.6% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,055.5% | -680.8% | -6,384.1% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,071.6% | -722.1% | -6,635.3% | – |
| EPS Diluted | -0.357 | -0.961 | -3.777 | -4.635 |
| % Growth | 62.8% | 74.6% | 18.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |